Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Dec;16(4):466-478.
doi: 10.1007/s11938-018-0197-8.

Pancreatic Cancer and Diabetes Mellitus

Ayush Sharma  1 , Suresh T Chari  2
Affiliations
Review

Pancreatic Cancer and Diabetes Mellitus

Ayush Sharma et al. Curr Treat Options Gastroenterol. 2018 Dec.

Abstract

Purpose of review: The relationship between pancreatic ductal adenocarcinoma (PDAC) and diabetes mellitus (DM) is complex. We reviewed the recent medical literature regarding the effect of anti-diabetic medication on PDAC risk and survival, risk of PDAC in DM, and role of DM in early detection of PDAC.

Recent findings: Studies report that while some anti-diabetic medications (e.g., metformin) may decrease the risk of PDAC, others (insulin, sulfonylureas and incretin-based therapies) may increase the risk. However, these observations may be subject to protopathic biases. Metformin's anti-tumor activity may have influence overall survival of PDAC, but epidemiological reports have largely been inconsistent to defend these findings due to heterogeneous methodologies. There is congruent data to support the association between DM and PDAC, with an inverse relationship to DM duration. Older subjects with new-onset DM are the only known high-risk group for PDAC, and strategy using this group for early detection has led to development of clinical risk prediction models that define a very high-risk PDAC group. Role of anti-diabetic medication in PDAC risk modification or survival is controversial. With successful efforts to distinguish type 2-DM from PDAC-DM using risk-stratifying models, there is an opportunity to initiate screening protocols for early detection of PDAC in a sub-set of DM subjects.

Keywords: Anti-diabetic medication; Early detection; Hyperglycemia; New-onset diabetes; Pancreatic cancer.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

Suresh Chari reports grants from NIH and the Kenner Family Research foundation, during the conduct of the study.

Ayush Sharma declares no conflict of interest.

Figures

Figure 1.
Figure 1.
Schematic diagram showing incidence risk of pancreatic cancer in currently known risk groups. Compared to long-standing diabetes, new-onset diabetes have a significantly higher risk. This risk further elevated with the clinical risk prediction model such as ENDPAC score.
See this image and copyright information in PMC

References

    1. Sah RP, Nagpal SJS, Mukhopadhyay D, Chari ST. New insights into pancreatic cancer-induced paraneoplastic diabetes. Nature Reviews Gastroenterology and Hepatology. 2013;10(7):423–33. - PMC - PubMed

    1. Andersen DK, Korc M, Petersen GM, Eibl G, Li D, Rickels MR et al. Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer. Diabetes. 2017;66(5):1103–10. doi: 10.2337/db16-1477.

      This reports highlights key research gaps in relationship between PDAC and DM as identified by experts at a symposium held at the American Diabetic Association 76th scientific session.

    1. Bosetti C, Rosato V, Buniato D, Zambon A, La Vecchia C, Corrao G. Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis. Oncologist. 2013;18(2):148–56. doi: 10.1634/theoncologist.2012-0302. - DOI - PMC - PubMed
    1. Colmers IN, Bowker SL, Tjosvold LA, Johnson JA. Insulin use and cancer risk in patients with type 2 diabetes: a systematic review and meta-analysis of observational studies. Diabetes Metab. 2012;38(6):485–506. doi: 10.1016/j.diabet.2012.08.011. - DOI - PubMed
    1. Bodmer M, Becker C, Meier C, Jick SS, Meier CR. Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis. Am J Gastroenterol. 2012;107(4):620–6. doi: 10.1038/ajg.2011.483. - DOI - PubMed